Heart Failure Clinical Trial
— QUARTOOfficial title:
QUARTET LEAD AND RESYNCHRONIZATION THERAPY OPTIONS To Investigate the Stimulatory Possibilities Offered by the Different Configurations Available for the Quartet Lead and Their Effect on Haemodynamic and Clinical Response.
| Verified date | February 2019 |
| Source | Abbott Medical Devices |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this Clinical Trial is to determine the percentage of patients whose
hemodynamic response improves with the different configurations offered by the new Quartet®
left ventricular lead, as a result of its four electrodes, with respect to the configurations
offered by a standard bipolar lead.
Furthermore, the optimal stimulation configuration will be determined from a comparison with
traditional configurations.
| Status | Completed |
| Enrollment | 51 |
| Est. completion date | September 2012 |
| Est. primary completion date | April 2012 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Patients with a Cardiac resynchronization Therapy Defibrillator device (CRT-D) and a Quartet® quadripolar electrode from St Jude Medical (used in "Single Site Pacing" mode) implanted in the left ventricle. 2. Patients who have provided written informed consent 3. Patients who are in sinus rhythm. 4. Patients older than 18 years of age. Exclusion Criteria: 1. Patients in atrial fibrillation at the time of the echocardiographic study of the enrollment visit. 2. Patients with valvular disease. 3. Patients in functional class New York Heart Association (NYHA) IV 4. Patients for whom echocardiography images suitable for determining the cardiac output cannot be obtained. 5. Patients whose device has been changed/upgraded. 6. Pregnant patients. 7. Patients who do not fulfill all the inclusion criteria. 8. Patients who are unable to provide written informed consent |
| Country | Name | City | State |
|---|---|---|---|
| Spain | Hospital Clínico Universitario Virgen de la Victoria | Málaga |
| Lead Sponsor | Collaborator |
|---|---|
| Abbott Medical Devices |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Patients Whose Cardiac Output (CO) Value in Acute, as Measured Echocardiographically, Improves With the Different Stimulation Vectors Offered by the Quartet® Left Ventricular Electrode. | Enrollment visit (in the seven days after implantation of the device) | ||
| Secondary | Percent Difference Between the Best CO From Non-traditional Vectors and Best CO From Traditional Vectors | In patients with best CO obtained from Non-traditional, to calculate the percent difference between the best CO from Non-traditional vectors and best CO from Traditional vectors, vectors.This percentage was the CO from Non-traditional vectors minus CO from Traditional vectors then divided by CO from Traditional vectors. The Quartet® lead has 4 poles: Distal (D1), Mid 2 (M2), Mid 3 (M3) and Proximal (P4). The 3 Traditional vectors are the traditional configurations available in a standard bipolar lead: D1-M2, D1-Right Ventricular Coil (RVC) and M2-RVC. The 7 Non-traditional vectors are the additional configurations available in a Quartet® lead: D1-P4, M2-P4, M3-M2, M3-RVC, M3-P4, P4-M2 and P4-RVC. |
At enrollment | |
| Secondary | Cardiac Output (CO) With Different Configurations at Enrollment | Means of baseline non-paced CO, best CO obtained from traditional configurations and best CO obtained from all quadripolar configurations at enrollment. | Enrollment visit (in the seven days after implantation of the device) | |
| Secondary | Capture Threshold | Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied. Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, whilst maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode. |
Enrollment visit (in the seven days after implantation of the device) | |
| Secondary | Capture Threshold | Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied. Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, whilst maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode. |
6 months post-implant | |
| Secondary | Number of Vectors With Phrenic Nerve Stimulation (PNS) | Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied. Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, while maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode. |
Enrollment visit (in the seven days after implantation of the device) | |
| Secondary | Number of Vectors With Phrenic Nerve Stimulation (PNS) | Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied. Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, whilst maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode. |
At 6 months | |
| Secondary | Number of Patients With PNS in All Vectors | To calculate the number of patients that exhibit PNS in all traditional vector | At enrollment | |
| Secondary | Number of Patients With PNS in All Vectors, That Could be Avoided With a Non-traditional Vector | To calculate the number of patients, who exhibit PNS in all traditional vector, in which PNS could be avoided using a non-traditional vector | At enrollment | |
| Secondary | Number of Patients With PNS in All Vectors | To calculate the number of patients that exhibit PNS in all traditional vector | At 6 months | |
| Secondary | Number of Patients With PNS in All Vectors, That Could be Avoided With a Non-traditional Vector | To calculate the number of patients, who exhibit PNS in all traditional vector, in which PNS could be avoided using a non-traditional vector | At 6 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
| Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
| Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
| Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
| Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
| Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
| Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
| Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
| Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
| Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
| Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
| Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
| Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
| Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
| Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|